VLA viralytics limited
Add to My Watchlist 0.00% ! $1.75

New CAVATAK & KEYTRUDA combo trial in NSCLC

  1. DavieJones
    255 Posts.
    lightbulb Created with Sketch. 35
    clock Created with Sketch.
    09/07/16
    10:55
    Post #: 18231114
    It looks like a new trial is about to commence with CAVATAK & KEYTRUDA in advanced NSCLC, to be sponsored by the Olivia Newton-John Cancer Research Institute (with Merck & Viralytics as collaborators).

    The trial protocol looks fairly similar to the STORM part B trial (NSCLC component) but it's being conducted in Melbourne, which is great to see.

    https://clinicaltrials.gov/ct2/show/NCT02824965?term=NCT02824965&rank=1

    .
    VLA Price at posting: 96.5¢ Sentiment: Buy Disclosure: Held
    Likes Created with Sketch. 21  Upvote
    lightbulb Created with Sketch.  Great analysis
    Stroke 3 Created with Sketch. Comments Created with Sketch. Reply

  2. Top Stories

 

Featured News

NEWS Gold producers Alkane and Mandalay make merger official
right-arrow Created with Sketch.
AII Building assets, producing critical minerals and slashing dependency on China
right-arrow Created with Sketch.
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
Add to My Watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.